Sitagliptin

Nomen chemicum:

Sitagliptin (INN, antea MK-0431 notum ac sub nomine commercii Januviae venditum) est oralis antihyperglycemica (medicamentum anti-diabeticum) de dipeptidylo peptidase-4 (DPP-4) inhibitoris classis.

SMILES Code:

O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F.O=P(O )(O)O.[H]O[H]

InChi Code:

InChI=1S/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27- 13(7-26)24-25-15(27)16(20,21)22; H3,1,2,3,4);

InChi Key:

GQPYTJVDPQTBQC-KLQYNRQASA-N

Keyword:

Sitagliptin,Sitagliptin phosphate, Januvia, Glactiv, ONO-5435, MK-0431, L-000224715, 654671-77-9,654671-78-0, 486460-32-6

Solubilitas:Solutum in DMSO

Repono:0 - 4°C ad terminum brevem (dies ad septimanas), vel -20°C ad terminum longi (menses).

Descriptio:

Sitagliptin (INN, antea MK-0431 notum ac sub nomine commercii Januviae venditum) est oralis antihyperglycemica (medicamentum anti-diabeticum) de dipeptidylo peptidase-4 (DPP-4) inhibitoris classis. Hoc enzyme-inhibito medicamento vel solum vel in compositione cum aliis agentibus antihyperglycemicis oris (ut metformin vel thiazolidinedione) pro curatione diabete melliti generis 2. Utilitas huius medicamenti est. eius effectus laterales inferiores (eg, minus hypoglycemia, lucrum minus pondus) in valore sanguinis glucosi. Exenatide (Byetta) etiam suo effectu in systemate incretino operatur.

Target: DPP-4